Zepbound reported $517.4 million in sales for the quarter, even as most doses of the drug slipped into shortages in the U.S.. Read this story
Zepbound reported $517.4 million in sales for the quarter, even as most doses of the drug slipped into shortages in the U.S.. Read this story
More from CNBC | Business Biotechnology Biotech and Pharmaceuticals Pharmaceuticals Health care industry Earnings Breaking news Eli Lilly and Co United States business news cnbc Articles US: News Companies Business News Health & Science source:tagname:CNBC US Source Eli Lilly and Company NYSE:LLY